Adovate Overview
- Year Founded
-
2023
- Status
-
Private
- Employees
-
22
- Latest Deal Type
-
Early Stage VC
- Investors
-
4
Adovate General Information
Description
Operator of an adenosine drug development platform intended to create novel therapeutics targeting adenosine receptors involved in major diseases. The company specializes in designing patented compounds with favorable physicochemical characteristics and optimized distribution kinetics that overcome historical limitations of adenosine receptor-targeting drugs, enabling doctors to advance previously challenging therapeutic targets into viable treatment options.
Contact Information
Website
www.adovate.comCorporate Office
- 1180 Seminole Trail
- Suite 495
- Charlottesville, VA 22901
- United States
Corporate Office
- 1180 Seminole Trail
- Suite 495
- Charlottesville, VA 22901
- United States
Adovate Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC | 01-Aug-2025 | Completed | Product Development | |||
| 1. Accelerator/Incubator | 15-May-2025 | Completed | Product Development |
Adovate Patents
Adovate Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022275564-A1 | Cyclic amide-containing pyridyl xanthines as a 2b antagonists | Pending | 18-May-2021 | ||
| CA-3218963-A1 | Cyclic amide-containing pyridyl xanthines as a2b antagonists | Pending | 18-May-2021 | ||
| US-11814387-B2 | Cyclic amide-containing pyridyl xanthines as a2b antagonists | Active | 18-May-2021 | ||
| US-12269828-B2 | Cyclic amide-containing pyridyl xanthines as a2b antagonists | Active | 18-May-2021 | ||
| US-20220402919-A1 | Cyclic amide-containing pyridyl xanthines as a2b antagonists | Active | 18-May-2021 | C07D473/06 |
Adovate Signals
Adovate Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Blue Valley Fund One | Venture Capital | Minority | ||
| VentureSouth | Angel Group | Minority | ||
| Johnson & Johnson Innovation - JLABS | Accelerator/Incubator | |||
| Virginia Catalyst | University |
Adovate Acquisitions (1)
Adovate’s most recent deal was a Merger/Acquisition with Purnovate. The deal was made on 30-Jun-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Purnovate | 30-Jun-2023 | Merger/Acquisition | Drug Discovery |
Adovate FAQs
-
When was Adovate founded?
Adovate was founded in 2023.
-
Where is Adovate headquartered?
Adovate is headquartered in Charlottesville, VA.
-
What is the size of Adovate?
Adovate has 22 total employees.
-
What industry is Adovate in?
Adovate’s primary industry is Drug Discovery.
-
Is Adovate a private or public company?
Adovate is a Private company.
-
What is Adovate’s current revenue?
The current revenue for Adovate is .
-
Who are Adovate’s investors?
Blue Valley Fund One, VentureSouth, Johnson & Johnson Innovation - JLABS, and Virginia Catalyst have invested in Adovate.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process